as 09-18-2025 3:32pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Founded: | 2015 | Country: | United Kingdom |
Employees: | N/A | City: | LONDON |
Market Cap: | 2.6B | IPO Year: | 2018 |
Target Price: | $40.83 | AVG Volume (30 days): | 402.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.07 | EPS Growth: | N/A |
52 Week Low/High: | $17.82 - $37.34 | Next Earning Date: | 10-28-2025 |
Revenue: | $529,332,000 | Revenue Growth: | 56.18% |
Revenue Growth (this year): | 37.21% | Revenue Growth (next year): | 11.99% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 15 '25 | Sell | $36.73 | 16,400 | $597,975.80 | 34,908 | |
Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 5 '25 | Sell | $35.66 | 13,389 | $477,451.74 | 34,908 | |
Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 4 '25 | Sell | $35.52 | 85,271 | $3,028,825.92 | 34,908 | |
Moat Ross | KNSA | CHIEF CORP. & COMM. OFFICER | Sep 4 '25 | Sell | $35.31 | 3,523 | $124,397.13 | 9,415 | |
Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 3 '25 | Sell | $35.50 | 15,091 | $535,730.50 | 34,908 | |
Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Sep 3 '25 | Sell | $34.84 | 11,000 | $383,240.00 | 38,011 | |
Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Aug 18 '25 | Sell | $34.11 | 16,200 | $547,141.00 | 34,908 | |
Malley Thomas | KNSA | N/A | Aug 14 '25 | Sell | $33.09 | 78,233 | $2,588,729.97 | 12,546 | |
Malley Thomas | KNSA | N/A | Aug 13 '25 | Sell | $33.32 | 50,129 | $1,670,298.28 | 12,546 | |
Malley Thomas | KNSA | N/A | Aug 12 '25 | Sell | $32.40 | 49,407 | $1,600,786.80 | 12,546 |
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Zacks
7 days ago
Zacks
9 days ago
MT Newswires
10 days ago
MT Newswires
a month ago
MT Newswires
3 months ago
MT Newswires
3 months ago
GlobeNewswire
3 months ago
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.